Sepracor, Inc.

Other

Georgetown University

Nancy M Gray

James W Young

William J Wechter

Raymond L Woosley

Patricia C Contreras

Yiwang Chen

Methods and compositions are disclosed utilizing optically pure (&#x2212;) pantoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of pantoprazole. The optically pure (&#x2212;) isomer is also useful for the treatment of gastroesophageal reflux. (&#x2212;) Pantoprazole is an inhibitor of Hrelease and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

Method for treating gastric disorders using optically pure (&#x2212;) pantoprazole

Methods are disclosed utilizing the optically pure (+) isomer of cisapride. This compound is a potent drug for the treatment of gastro-esophageal reflux disease while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of cisapride.

Methods for treating gastro-esophageal reflux disease using optically

Methods are disclosed utilizing the optically pure (-) isomer of cisapride. The (-) isomer of cisapride also exhibits longer duration of action than does racemic cisapride and is useful for treatment of disorders of the central nervous system.

Methods for treating disorders associated with the central nervous

Methods and compositions are disclosed utilizing the optically pure (-) isomer of ketoconazole. This compound is a potent drug for the treatment of local and systemic fungal, yeast, and dermatophyte infections, while avoiding the concomitant liability of adverse effects associated with the racemic mixture of ketoconazole.

Methods ad compositions of (-) ketoconazole for treating fungal yeast

Methods and compositions are disclosed utilizing optically pure R-(-)-casodex for the treatment of androgen-dependent prostate cancer, while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of casodex. R-(-)-casodex is an antiandrogen and is therefore useful in the treatment of other conditions supported by androgen or caused by elevated androgen levels. Such conditions include benign prostatic hypertrophy or hyperplasia, acne and hirsutism.

Methods and compositions for treating androgen-dependant diseases using

The optically pure (-) isomer of cisapride is useful for the treatment of dyspepsia and such other conditions as may be related to the activity of (-) cisapride as a prokinetic agent, such as gastroparesis, constipation, post-operative ileus, and intestinal pseudo-obstruction, without the concomitant liability of adverse effects associated with the racemic mixture of cisapride. The (-) isomer of cisapride also exhibits longer duration of action than does racemic cisapride and is useful for treatment of disorders of the central nervous system.

Methods for treating gastrointestinal motility dysfunction using

Methods are disclosed utilizing the optically pure (+) isomer of cisapride. The optically pure (+) isomer of cisapride is useful for the treatment of dyspepsia and such other conditions as may be related to the activity of (+) cisapride as a prokinetic agent, such as gastroparesis, constipation, post-operative operative ileus, and intestinal pseudo-obstruction, without the concomitant liability of adverse effects associated with the racemic mixture of cisapride. The (+) isomer of cisapride also exhibits longer duration of action than does racemic cisapride and is useful for treatment of disorders of the central nervous system.

Methods and compositions are disclosed utilizing optically pure (-) pantoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of pantoprazole. The optically pure (-) isomer is also useful for the treatment of gastroesophageal reflux. (-) Pantoprazole is an inhibitor of H.sup.+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

Methods and compositions for treating gastric disorders using optically

Methods are disclosed utilizing optically pure (-) cetirizine for the treatment of seasonal and perennial allergic rhinitis in humans while avoiding the concomitant liability of adverse effects associated with the racemic mixture of cetirizine. The optically pure (-) isomer is also useful for the treatment of allergic asthma.

Methods for treating allergic disorders using optically pure (-)

Methods are disclosed utilizing optically pure (-)-zileuton for the treatment of asthma in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of zileuton.

Methods for treating asthma using optically pure (-)-zileuton

Methods are disclosed utilizing the optically pure (+) isomer of cisapride. This compound is a potent drug for the treatment of gastro-esophageal reflux disease while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of cisapride. This compound is also useful in treating or preventing emesis while substantially reducing adverse effects associated with racemic cisapride. The optically pure (+) isomer of cisapride is also useful for the treatment of dyspepsia and such other conditions as may be related to the activity of (+) cisapride as a prokinetic agent, such as gastroparesis, constipation, post-operative ileus, and intestinal pseudo-obstruction, without the concomitant liability of adverse effects associated with the racemic mixture of cisapride. The (+) isomer of cisapride also exhibits longer duration of action than does racemic cisapride and is useful for treatment of disorders of the central nervous system.

Methods are disclosed utilizing the optically pure (+) isomer of cisapride. This compound is useful in treating emesis while substantially reducing adverse effects associated with racemic cisapride.

Methods for treating gastro-esophageal reflux disease and other

Methods are disclosed utilizing optically pure (+) cetirizine for the treatment of urticaria in humans while avoiding the concomitant liability of adverse effects associated with the racemic mixture of cetirizine.

Methods for treating urticaria using optically pure (+) cetirizine

Methods are disclosed utilizing the optically pure (-) isomer of cisapride. This compound is a potent drug for the treatment of gastro-esophageal reflux disease while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of cisapride. This compound is also useful in treating or preventing emesis while substantially reducing adverse effects associated with racemic cisapride.

Methods for treating gastro-esophageal reflux disease and emesis with

Methods are disclosed utilizing optically pure R(-) etodolac for the treatment of pain, including but not limited to pain associated with toothaches, headaches, sprains, joint pain and surgical pain, for example dental pain and ophthalmic pain, while substantially reducing adverse effects which are associated with the administration of the racemic mixture of etodolac. The optically pure R(-) etodolac is also useful in treating pyrexia while substantially reducing the adverse effects associated with the administration of the racemic mixture of etodolac.

Growing community of inventors

Marlborough, MA, United States of America

Nancy M Gray